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Care Unit
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Abstract
Background: Although neonates and young infants with cholestasis are commonly treated with either
phenobarbital or ursodeoxycholic acid (ursodiol), there is no evidence that phenobarbital is effective for this
indication. Our objective was to compare the effectiveness of ursodiol and phenobarbital for the treatment of
cholestasis in a diverse NICU population.
Methods: This is a retrospective cohort study including infants with cholestasis who were admitted to a Level IV
NICU between January 2010 and December 2015. Drug courses of phenobarbital and ursodiol were identified
within the medical record, and medical, demographic, and drug information were extracted. The primary outcome
was reduction in direct bilirubin.
Results: Sixty-eight infants provided a total of 112 courses of drug therapy for comparison. Diverse medical
diagnoses were captured in the patient cohort. Ursodiol was significantly more effective in reducing direct bilirubin
than was phenobarbital (− 1.89 vs + 0.76 mg/dL; − 33.33 vs + 13.0 umol/L, p-value 0.03), even after controlling for
baseline cholestasis severity, intrauterine growth restriction status, and lipid lowering therapy (− 2.16 vs + 0.27 mg/
dl; − 36.94 vs + 4.62 umol/L, p-value 0.03). There was no improvement in direct bilirubin in the majority of infants
treated with phenobarbital.
Conclusions: Phenobarbital, as compared to ursodiol, has limited efficacy for the reduction of direct bilirubin in
neonates and young infants with cholestasis. Given new data regarding the potential neurotoxicity of
phenobarbital in the developing brain, providers may choose to avoid phenobarbital in the treatment of cholestasis
in infants.
Keywords: Neonate, Cholestatic jaundice, Ursodiol, Phenobarbital, Neonatal intensive care unit

Background
Hepatic cholestasis is the result of impaired balance between bile acid uptake and efflux. Abnormal hepatic accumulation of bile salts leads to disruption of cell
membranes and cellular organelles resulting in necrosis,
inflammation, and fibrosis. Cholestasis is commonly encountered in the neonatal intensive care unit (NICU) as
a result of multiple medical conditions, including extreme prematurity, growth restriction, and sepsis [1].
Additionally, congenital anomalies of the gastrointestinal
* Correspondence: trlewis@cmh.edu
1
Department of Pediatrics, Children’s Mercy Hospital, University of Missouri
Kansas City School of Medicine, 2401 Gillham Rd, Kansas City, MO 64108,
USA
Full list of author information is available at the end of the article

tract requiring surgery and other medical conditions requiring prolonged parenteral nutrition are associated
with cholestasis. Given the known hepatotoxic effects of
bile salt stasis, physicians often treat cholestasis with
multiple modalities, including IV lipid limiting [2] and
the medications ursodiol (ursodeoxycholic acid) or
phenobarbital.
Ursodiol is the only drug approved by the Food and
Drug Administration for use in adult cholestatic conditions. Ursodiol protects injured cholangiocytes against
the toxic effects of bile acids and stimulates bile acid secretion via calcium-dependent mechanisms. Additionally, it directly modulates transcription of transporters
and inhibits bile-acid induced hepatocyte apoptosis [3,
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4]. Ursodiol is proven effective at treating parenteral
nutrition-associated cholestasis in small cohorts of infants [5, 6], but is not used as prophylaxis in high-risk
neonates [7, 8].
Phenobarbital acts via the nuclear receptor called constitutive androstane receptor (CAR), controlling hepatocellular metabolizing enzymes and transporters.
Phenobarbital improves cholestasis in a small cohort
of majority adult patients with anatomic abnormalities, including primary biliary cirrhosis, sclerosing
cholangitis, and intrahepatic biliary hypoplasia [9], but
there is no evidence that it is effective at treating
neonatal cholestasis. There is recent concern that
phenobarbital carries more risk than previously appreciated. Specifically, animal models of the developing
brain have shown that phenobarbital leads to neuronal apoptosis [10, 11] and long-term behavioral
toxicity [12].
Given the limited evidence for efficacy and increased evidence for toxicity with phenobarbital, we
aimed to compare the two drugs ursodiol and phenobarbital for effectiveness in treatment of cholestasis in
a diverse cohort of infants. We hypothesized that
ursodiol would be more effective at reducing direct
bilirubin (DBili), a surrogate marker for hepatic cholestasis. Our primary outcome was change in direct
bilirubin, with a secondary outcome of direct bilirubin
at the end of drug therapy.

Methods
This retrospective cohort study was approved by the
Children’s Mercy Institutional Review Board prior to
data extraction. Eligible infants between January 2010
and December 2015 were identified using the variable
“highest direct bilirubin” in the Children’s Hospitals
Neonatal Database (CHND), and all children admitted
to the Children’s Mercy Intensive Care Nursery with a
documented direct bilirubin > 3.0 mg/dl (51.34 umol/)
were identified to eliminate cases of mild cholestasis. Infants were randomly selected from this list, without
knowledge of drug treatment or bilirubin changes, for
inclusion in the study cohort. Infants included in the
study were treated with ursodiol and/or phenobarbital
per standard clinical care in the NICU, at the discretion
of the neonatologist at the time of treatment. There is
no protocol which dictates drug treatment for cholestasis, but most practitioners use phenobarbital while an infant is not enterally fed and ursodiol when on feeds.
Because we could not extract important study data from
outside charts, infants were excluded if they were transferred to our NICU already on medication for cholestasis, or if they were discharged to another NICU on
cholestasis medications.
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Study variables

Because many infants were exposed to more than one
course of medication treatment for cholestasis, we defined the research unit as a course of medication administration, e.g. ursodiol for 25 days. All relevant variables
were then extracted for that medication course, including direct bilirubin levels when the medication was
started and stopped. If the direct bilirubin was measured
a few days before stopping the medication, we used the
date of the last bilirubin measurement as the stop date.
If drug treatments overlapped, we only used data until
the day before the second drug was added in order to
exclude overlapping drug effect. Medication courses
were excluded if they were less than 1 week long because we felt that a meaningful change in cholestasis
could not be appreciated with such a short treatment
course.
Demographic data (gestational age, race, gender, birthweight), major medical diagnoses, and drug data (daily
dose, length of therapy) were collected from the charts
of eligible infants. Data about potential confounding variables including nutrition (lipid lowering treatment, age
when enteral nutrition achieved) were extracted from
each patient chart. Lipid lowering refers to the practice
of decreasing parenteral intralipid administration from
3 mg/kg/day to 1 mg/kg/day and is used as first line
treatment of TPN-associated cholestasis in the NICU
where this study was performed. Some infants with cholestasis with not be treated with lipid lowering if they
have relative contraindications such as poor growth or
inability to tolerate higher glucose infusion rates or protein to supplement calories lost in lipid lowering.
Statistical analysis

To calculate sample size, we assumed based on clinical
experience that ursodiol would have a much larger effect
on improving direct bilirubin than would phenobarbital
(average improvement in DBili 3 mg/dL; 51.34 umol/L
vs 0.3 mg/dL; 5.13 umol/L), with a standard deviation of
4 mg/dL (68.45 umol/L). Using a two-sided significance
value of .05 and a two group t-test, an N of 35 in each
group provides 80% power to detect a difference.
Two analyses were performed. The first analysis included only the first course of drug therapy to eliminate
any carryover effect from treatment with a prior medication for cholestasis. The second analysis included all
drug courses, and included a variable to account for
prior drug therapy within a 14-day window. Categorical
variables were compared between the two drug treatment groups using Chi-squared analysis. Continuous
variables were compared between the two drug groups
using Wilcoxon rank sums analysis. Univariate analysis
of the primary outcome of change in direct bilirubin was
performed using analysis of variance (ANOVA), and
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multivariate analysis was performed using mixed effect
regression modeling. We controlled for confounders including direct bilirubin at start of therapy (baseline severity), intrauterine growth restriction (IUGR), and lipid
lowering (a commonly used alternative treatment for
cholestasis). Although these variables were not statistically significantly different between the drug groups,
there is biological plausibility that these clinical confounders could affect the scientific comparison. All statistical analyses were performed using SAS version 9.4.
Two infants with extreme phenotypes were excluded:
(1) a preterm, IUGR infant with congenital diaphragmatic hernia who died on extracorporeal membrane
oxygenation (ECMO) at day 14 with a direct bilirubin of
48 who was treated with phenobarbital, and (2) a
full-term infant with congenital leukemia who developed
cholestasis as a chemotherapy side effect in whom
anti-cholestatic medications were used prophylactically.

Results
Data on 68 infants were extracted to obtain 68 first
courses of drug therapy for comparison and 112 total
courses of drug therapy for comparison. 49% of patients
had one eligible drug course, 40% had two eligible
courses, and 11% had more than two eligible courses.
The primary medical diagnoses of the patients in the cohort are listed in Table 1.
The gestational ages, gender, race, and IUGR status
did not differ significantly between the two patient
groups (Table 2). There were similar rates of treatment
with lipid lowering at drug start and similar lengths of
drug treatment. Doses of phenobarbital and ursodiol
were within standard of care ranges. All doses of phenobarbital were given intravenously and all doses of ursodiol were given enterally. The direct bilirubin at start of
Table 1 Patient cohort medical diagnoses

drug therapy was similar between the two groups. For
the first course only analysis, 29% of infants were on 70/
kg feeds and 16% of infants were on 140/kg feeds in the
phenobarbital group. 89% of infants were on 70/kg feeds
and 62% of infants were on 140/kg feeds in the ursodiol
group. For the all courses analysis, 43% of infants were
on 70/kg feeds and 30% of infants were on 140/kg feeds
in the phenobarbital group. 86% of infants were on 70/
kg feeds and 60% of infants were on 140/kg feeds in the
ursodiol group.
The results of the drug comparisons are displayed in
Table 3. In the primary analysis using the first course of
drug therapy only, ursodiol was significantly more effective in reducing direct bilirubin than was phenobarbital
(− 1.89 vs + 0.76 mg/dl; − 33.33 vs + 13.0 umol/L, p-value
.03), even after controlling for baseline cholestasis severity,
IUGR status, and lipid lowering therapy (− 2.16 vs +
0.27 mg/dl; − 36.94 vs + 4.62 umol/L, p-value .03). In the
analysis including all treatment courses, ursodiol was
again significantly more effective in reducing direct bilirubin than was phenobarbital (− 3.96 vs + 0.28 mg/dl;
− 67.73 vs + 4.79 umol/L, p-value <.01). Figure 1 is a
spaghetti plot of change in direct bilirubin for (a) first
courses, and (b) all drug courses.

Table 2 Patient variables by drug (first course of drug therapy)
Phenobarbital
(N = 37)

Ursodiol
(N = 31)

22–28 weeks

38

45

28–34 weeks

40

32

> 34 weeks

22

23

57

71

Gestational Age at Birth (%)

Male (%)

Diagnosis

N (68)

Preterm, Uncomplicated

11

Preterm, Sepsis

7

Preterm, Spontaneous Intestinal Perforation

2

Surgical NEC

12

Medical NEC

7

Congenital Heart Diseasea

6

Congenital Diaphragmatic Hernia (CDH)

4

Malrotation ± Bowel Atresia

4

Gastroschisis / Omphalocele

3

Other

12

ECMO

2

Other: 1 Biliary atresia, 3 fullterm with pneumonia/sepsis (2 on ECMO), 3
hepatitis / liver failure of unknown etiology, 1 congenital CMV, 1
homocystinuria, 1 undiagnosed genetic syndrome with multiple anomalies, 1
panhypopituitarism with multiple anomalies, 1 preterm with congenital
lung malformation
a
one with documented medical NEC. NEC = necrotizing enterocolitis

0.2261
0.1439

Caucasian

58

61

African American

20

32

Other

22

7

IUGR (%)

19

32

0.2058

On Restricted Lipids at
start of drug therapy (%)

46

39

0.5479

Length of Drug Course a

17 (13,38)

17 (12,32)

0.4557

4.48 (3.84, 5.05)

27.43
(22.39,29.00)

n/a

Dose (mg/kg/day)
2

0.7628

Race (%)

1

p-value

a

Direct Bilirubin at start of
drug therapy
mg/dLb
umol/L
a

b

0.8458
7.1 (3.98)

6.9 (4.92)

121.1 (68.1)

118.0 (84.2)

: Median (lower quartile, upper quartile); b: Mean (SD). IUGR = in utero
growth restriction
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Table 3 Cholestasis outcomes by drug treatment
Phenobarbital

Ursodiol

p-value

Univariate analysis (first course only)
Change in direct Bilirubin

0.03

mg/dl

+ 0.76

−1.89

umol/L

+ 13.0

−32.3

mg/dl

7.84

4.98

umol/L

134.1

85.2

Direct Bili at end of drug therapy

0.02

Adjusted for direct Bilirubin at start of drug therapy
Change in direct Bilirubin
First course

0.01

mg/dl

+ 0.81

−1.95

umol/L

+ 13.85

- 33.35

mg/dl

+ 0.66

−3.63

umol/L

+ 11.29

−62.08

All Courses

<0.01

Direct Bili at end of drug therapy (mg/dl)
First course

0.01

mg/dl

7.79

5.03

umol/L

133.24

86.03

All Courses

<0.01

mg/dl

8.27

3.98

umol/L

141.45

68.07

Adjusted for direct Bilirubin at start of drug therapy, IUGR and limited
lipids
Change in direct Bilirubin
First course

0.03

mg/dl

+ 0.27

−2.16

umol/L

+ 4.62

−36.94

mg/dl

+ 0.28

−3.96

umol/L

+ 4.79

−67.73

All Courses

≠

< 0.01

Direct Bili at end of drug therapy (mg/dl)
First Course

0.03

mg/dl

7.25

4.83

umol/L

124.0

82.61

All Coursesa

< 0.01

mg/dl

7.89

3.65

umol/L

134.95

62.43

The first course analysis compares 37 phenobarbital to 31 ursodiol courses.
The all course analysis compares 46 phenobarbital to 66 ursodiol courses. aThe
all course analysis was also adjusted for a binary variable accounting for
previous phenobarbital or ursodiol exposure in prior 14 days

Discussion
This is the first study comparing effectiveness of ursodiol vs phenobarbital for the treatment of cholestasis in
infants. In a real world NICU population, our results

show that phenobarbital, on average, causes no improvement in direct bilirubin. Ursodiol is associated with
more improvement in direct bilirubin and a lower direct
bilirubin at the end of drug therapy. Although it is not
typical to compare an IV formulation (phenobarbital) to
an enteral formulation of another drug (ursodiol), we
feel this comparison is meaningful because these are the
two drugs used to treat cholestasis in the NICU in clinical care and the formulations in which they are given
for the same diagnosis. A randomized controlled trial of
these off-label, off patent medications is unlikely to
occur, and thus a comparative cohort study is the
current best evidence we can provide.
Ursodiol is the standard of care drug for cholestasis
management, and comparing this to phenobarbital, a
drug used without evidence of efficacy, is the only way
to ascertain phenobarbital’s utility for this indication.
Many clinicians use phenobarbital for cholestasis when
an infant is critically ill and not yet enterally fed or on
low percent of enteral feeds, while awaiting the ability to
use ursodiol once the infant has improved enteral feeding tolerance. T our knowledge, this is the first data
which shows a lack of efficacy of phenobarbital in the
treatment of neonatal cholestasis, and suggests that clinicians may consider avoiding phenobarbital treatment
and waiting for sufficient enteral feeds to start ursodiol
as the treatment of choice.
Despite lack of evidence, clinicians still use phenobarbital to treat neonatal and infant cholestasis. In a retrospective cohort study of neonates receiving phenobarbital
for neurologic treatment (5 mg/kg/day), 66% of
phenobarbital-treated infants developed cholestasis, as opposed to 33% of untreated controls [13], providing indirect
evidence for lack of utility in cholestasis. In studies of
drug-augmented hepatobiliary scintigraphy, results are
mixed in regards to phenobarbital efficacy. When 50 infants with non-excreting phenotype on HIDA scan were
randomized to phenorarbital, ursodiol or placebo, there
was no increase in biliary excretion with any treatment
[14]. In a direct comparison of the two drugs, the specificities of diagnosis of biliary atresia on drug-augmented
scintigraphy were 80% for phenobarbital and 96.6% for
ursodiol [15].
In addition to lack of efficacy, there is animal data which
supports the role of phenobarbital as a neurotoxin. Normal rat pups equivalent in developmental age to human
newborns were exposed to phenobarbital and areas of
brain were examined for injury at 24 h. As compared to
control, phenobarbital-treated rats had significantly increased levels of neuronal apoptosis in multiple brain regions [10]. In a different study, normal rat pups exposed
to a single dose of phenobarbital at human newborn
equivalent age exhibited impaired physiologic maturation
in synaptogenesis among surviving neurons, suggesting
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Fig. 1 Change in Direct Bilirubin by Drug Treatment. a First Course Only: Direct Bilirubin improved in 37% of phenobarbital courses and 70% of
ursodiol courses. b All Drug Courses: Direct Bilirubin improved in 39% of phenobarbital courses and 77% of ursodiol courses

that early life exposure can potentially impact cognitive
and behavioral outcomes [16]. Rats with a single exposure
to phenobarbital during a critical window of brain development showed schizophrenia-like behavioral abnormalities as adults, suggesting that early neuronal injury and
disordered synaptogenesis can predispose to psychiatric
illness [17]. When used for cholestasis, phenobarbital is
dosed daily for multiple days (median of 17 days in our
cohort), and this prolonged dosing during a critical period
of brain development may place infants at risk for neuronal abnormalities.
As with all retrospective cohort studies, our study
has some limitations. First, since other markers of
hepatic injury (AST/ALT, GGT, and hepatic ultrasound) are not closely followed clinically in many infants with cholestasis, direct bilirubin was the only
universally available marker of cholestasis available as
a surrogate marker of disease. Second, most infants
with cholestasis in our cohort were treated with
multiple courses of medications for cholestasis. To
account for the effects of a prior drug course influencing the clinical results of a subsequent drug course,
we did a primary analysis comparing only first
courses of drug therapy. Third, given the critically ill
condition of the patient population, most infants are
not enterally fed initially and are treated with intravenous phenobarbital until on sufficient enteral feeds
to tolerate ursodiol (an enterally dosed medication).
This is the reality of the care of these infants and is
reflected in the study results. We understand that enteral feedings could have confounded the association
between ursodiol therapy and improvement in direct
bilirubin because enteral feeds are themselves associated with improvement in cholestasis. Although enteral feeds likely augment the improvement of direct

bilirubin seen with ursodiol, it seems unlikely that
this accounts for the entire difference we observed
between the two medications.
Strengths of this research include the diversity of
medical diagnoses among the patients included in the
cohort, making the results widely generalizable for
NICU patients. Additionally, the narrow range of
phenobarbital and ursodiol daily doses minimized the
effect of drug dosing variability on the outcome.
Lastly, we were able to account for the other main
treatment modality for cholestasis, IV lipid limiting,
in the comparative analysis.
There are potential new drugs for the treatment of
cholestasis, such as obethicolic acid, a farnesoid C receptor (FXR) agonist, which regulates a wide variety
of genes critical to bile acid synthesis and transport.
FXR agonism decreases synthesis of bile acids in hepatocytes and increases transport of bile acids out of
the cells, overall reducing the cytotoxic injury to hepatocytes. This drug was FDA approved this drug in
May 2016 for the treatment of primary biliary cholangitis in combination with ursodiol. The pharmacokinetics, safety and efficacy of this drug have not been
studies in neonates.

Conclusion
In conclusion, our study is the first to show that phenobarbital, when dosed over many days, does not significantly improve cholestasis in infants as compared to
ursodiol. The burgeoning evidence for neurotoxicity in
the developing brain associated with phenobarbital use
may steer a treating clinician towards the use of ursodiol
as the drug of choice for treatment of cholestasis in
neonates.
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